PTA is our method of choice if you want reproducible, efficient, and evenly amplified genomes from single cells for single nucleotide variant detection."
Bullard Professor of Neurology, Harvard Medical School Chief Division of Genetics, Boston Children’s Hospital Investigator, Howard Hughes Medical Institute
I have tried several whole-genome amplification methods, and none compare to the high reliability and high fidelity of PTA.”
Michael Lodato, Ph.D.
Assistant Professor, Department of Molecular, Cell, and Cancer Biology, University of Massachusetts Medical School
I am setting up my own lab and BioSkryb has been extremely supportive. We can use PTA to detect mutation with high-confidence, sensitivity, and accuracy in single cells. This really opens up a lot of interesting avenues for us, and places us in the right position to discover some very exciting new biology.”
The BioSkryb team was a great partner in assisting us with single-cell sequencing and analysis. They were responsive to our unique needs and the results and insights their technology provided far exceeded our expectations. BioSkryb’s commitment to supporting us in our fight against cancer using cell and gene therapies was present every step of the way. We highly recommend them for their products, services, and a customer-centric approach.”
Working with Bioskryb Genomics was an amazing experience. In part because of the quality of the training and support they provided during the assay setup, in part because their method generates gorgeous data. While acting as Director of the Personalized Genomic Medicine Division at Columbia University in the mid 2010s, I experimented with single-cell genome amplification. I quickly gave up on that effort because of the poor uniformity and high artifact content of the PCR-based technologies. Using the Bioskryb Genomics method was really a revelation. The uniformity of amplification and the specificity and sensitivity of both SNV and CNV detection was comparable to unamplified genome sequencing results. This technology represents a great promise for reproductive medicine as well as for other applications. Great contribution to science and medicine; Congratulations to the developers!”
I have worked with scientists from BioSkryb over the past year and a half. Their technology is cutting edge and produces data with amazing resolution. Breast cancer evolution described by both point mutations and copy number changes is apparent at the single cell level. Their staff have tremendous expertise and have been exceptional collaborators in generating data that will form the basis for manuscripts and grant proposals.”
Jeffrey R. Marks, PhD
Vice Chief, Division of Surgical Sciences, Professor in Surgery, Professor of Pathology, Duke University School of Medicine